Is Dulaglutide legal in New Zealand?

Medsafe's data sheet for Trulicity gives 12 August 2021 as the date of first approval. It is approved for improving blood sugar control in adults with type 2 diabetes and for reducing the risk of major cardiovascular events in adults with type 2 diabetes who have heart disease or several cardiovascular risk factors. Pharmac funds it through a Special Authority: the person must have type 2 diabetes and must not have reached their HbA1c target despite regular use of empagliflozin, metformin and vildagliptin for at least 6 months where clinically appropriate. It is not approved for weight management, and Pharmac describes it as one of two funded GLP-1 medicines for type 2 diabetes, alongside Victoza.